Brought to you by 
Taiba gets rights to sell Envarsus XR in MENA region for Veloxis
06 Jun 2017
Executive Summary
Veloxis Pharmaceuticals Inc. granted Taiba Healthcare exclusive rights to sell its organ transplant rejection therapy Envarsus XR in certain countries in the MENA (Middle East and North Africa) region.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Taiba gets rights to sell Envarsus XR in MENA region for Veloxis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice